Market Place
Sourcing Support
Saol Therapeutics Submits NDA to FDA for SL1009
03 Dec 2024 //
PR NEWSWIRE
Saol Announces Positive SL-1002 RAISE Limb Spasticity Results
30 Oct 2024 //
PR NEWSWIRE
Saol Therapeutics Announces Completion of Enrollment in Both the PII Trial
19 Sep 2023 //
PR NEWSWIRE
Saol Announces Enrollment in Pivotal PIII Trial for Rare Mitochondrial Disease
04 Oct 2022 //
PRNEWSWIRE
Saol enrols first subject in Phase II osteoarthritis trial
10 Aug 2022 //
CLINICAL TRIALS ARENA
Saol Therapeutics Begins Enrollment in PII COMPASS Trial of SL-1002
09 Aug 2022 //
PRNEWSWIRE
Amneal Acquires Saol Therapeutics’ Baclofen Franchise
05 Jan 2022 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.